The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and has been acknowledged as a leading cause of death among cirrhosis patients.Difficulties in early diagnosis and heterogeneity are obstacles to effective treatment, especially for advanced HCC.Liver transplantation (LT) is considered the best therapy for HCC.Although many biomarkers are being proposed, alpha-fetoprotein (AFP), which was identified over 60 years ago, remains the most utilized.Recently, much hope has been placed in the immunogenicity of AFP to develop novel therapies, such as AFP vaccines and AFP-specific adoptive T-cell transfer (ACT).This review summarizes the performance of AFP as a biomarker for HCC diagnosis and prognosis, as well as its correlation with molecular classes.In addition, the role of AFP in LT is also described.Finally, we highlight the mechanism and application prospects of two immune therapies (AFP vaccine and ACT) for HCC.In general, our review points out the prevalence of AFP in HCC, accompanied by some controversies and novel directions for future research.